A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study

NCT01673919 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Idiopathic Arthritis

Interventions

DRUG: tocilizumab [RoActemra/Actemra]

Sponsor

Hoffmann-La Roche